FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
US FDA approves J&J's ketamine-based therapy to treat depression
The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with ...
NJBIZ23h
J&J’s ketamine-based drug approved as standalone treatment
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
J&J's ketamine-based nasal spray Spravato approved by US FDA to treat depression
The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...
The FDA just approved this ketamine-derived nasal spray for depression treatment
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...
Inquirer on MSN2d
Ketamine a lifeline for severe depression patients in Singapore
Ketamine, the controlled drug best known as a horse tranquilizer or party supplement, has in the last four years become a ...
US FDA approves standalone use of J&J’s ketamine-derived depression treatment
The US Food and Drug Administration (FDA) has expanded the approval for Johnson & Johnson’s nasal spray Spravato to allow its standalone use in patients with depression, the company said on Jan 21.